Therapeutic Class-Based Panels: High-Throughput LC-MS/MS Analytical Services

In the competitive landscape of early drug discovery and preclinical development, the ability to rapidly assess a candidate compound against its therapeutic peers or within the context of a specific disease pathway is a strategic necessity. Creative Proteomics DMPK provides specialized Therapeutic Class-Based Panels, a high-throughput analytical solution designed for the simultaneous, absolute quantification of multiple drugs and their active metabolites within a single, validated analytical run.

Our expertise extends beyond simple concentration reporting. We bridge the gap between high-volume screening and expert bioanalytical method development, supporting researchers in the pharmaceutical and biotechnology sectors who require rigorous, high-resolution data to drive PK/PD modeling and lead optimization. By integrating our ISO 17025-certified laboratory environment with deep scientific knowledge in plasma and serum drug quantification, we deliver the technical depth needed for high-stakes R&D decisions.

Our therapeutic panels are structured to cover the most critical areas of modern drug research. Each section below represents a specialized analytical module optimized to resolve class-specific challenges.

Oncology Drug Panels

The oncology pipeline is increasingly focused on targeted therapies and complex combination regimens. We provide robust quantification across the four foundational pillars of modern cancer treatment:

• Tyrosine Kinase Inhibitors (TKIs): Encompassing over 40 clinically relevant TKIs (e.g., Imatinib, Gefitinib). We utilize advanced extraction to overcome intracellular accumulation and high protein binding in tissue and cell lysates.
• DNA Damage Response (DDR) Inhibitors: Specifically for PARP, ATR, and ATM inhibitors. Our assays achieve sub-ng/mL LLOQs, critical for minimal tumor biopsy samples.
• Hormone Therapy Agents: Optimized for ARPIs (e.g., Enzalutamide) and SERMs. We emphasize resolution of circulating active metabolites.
• Cytotoxic Chemotherapeutics: Accurate monitoring of taxanes and antimetabolites (e.g., Gemcitabine) with high matrix effect resolution in liver and kidney tissues.

Cardiovascular Drug Panels

Supporting the quantification of wide structural diversity including statins, lipid-regulators, anticoagulants (DOACs), and antihypertensives (ACE inhibitors, ARBs), often utilized in drug-drug interaction (DDI) screening.

Anti-Infective Drug Panels

Providing high-throughput screening for broad-spectrum antibiotics (beta-lactams, fluoroquinolones), antiviral agents (novel combination therapies), and lipophilic antifungals.

CNS Drug Panels

Specialized for neurotherapeutics including antipsychotics and antidepressants. We employ specialized homogenization and tissue drug quantification to evaluate blood-brain barrier (BBB) penetration.

Endocrine & Metabolic Drug Panels

Quantification of GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and hormonal regulators to support metabolic stability and early PK studies.

The primary technical bottleneck in multi-analyte panel development is the "Matrix Effect"—the suppression or enhancement of ionization caused by co-eluting components from biological samples. Creative Proteomics DMPK utilizes a rigorous scientific approach to ensure data precision:

• QqQ LC-MS/MS Excellence: Utilizing industry-standard systems such as Sciex 6500+ and Waters Xevo TQ-XS for exceptional dynamic range and sensitivity.
• UPLC Chromatography: Sub-2µm particle columns achieve superior resolution, critical for separating structural isomers and metabolites.
• Phospholipid Removal: Integration of specialized cleanup steps (e.g., hybrid SPE) to eliminate interferences that compromise sensitivity in early PK studies.

Our standardized yet flexible workflow ensures that each therapeutic panel project is executed with maximum accuracy:

• Custom Assay Design: Consultation to determine the specific drug list and proprietary analogs.
• Optimized Sample Preparation: Cryogenic bead-beating for tissue lysates and automated PPT/SPE for plasma.
• Methodological Calibration: Multi-point curves using stable-isotope labeled internal standards.
• MRM Optimization: Searching for the most sensitive transitions for every analyte.
• Quality Control (QC) Integrity: Incorporation of Low, Mid, and High QC samples with CV < 15%.
• Bioinformatic Integration: Post-analytical calculation and correlation with metabolic profiling.

Ensuring sample stability is paramount for stability and forced degradation studies. Proper sample collection and transit are critical for bioanalysis.